APOE ε4 is a potent AD risk factor. In the normal population 10-15% of people carry the
ε4 allele; among AD patients, up to 65% are
ε4 carriers (
Saunders et al., 1993;
Farrer et al., 1997). The mechanism through which
ε4 exerts its effect remains elusive, but possibilities include, promotion of tau hyperphosphorylation, reduction of beta-amyloid clearance, and inhibition of neurite outgrowth (
Kim et al., 2009). Previous studies of AD risk have shown that the
ε4 effect is more pronounced in females (
Payami et al., 1996;
Farrer et al., 1997;
Bretsky et al., 1999). With notable exceptions (
Corder et al., 2004;
Fleisher et al., 2005;
Lehmann et al., 2006), most studies have ignored this gender effect. No previous studies have investigated whether the interaction between gender and
APOE is detectable in healthy adults. Here we have shown that this interaction is detectable in healthy older adults using two distinct AD biomarkers in two independent samples.
DMN connectivity is a well-replicated imaging biomarker of AD (
Greicius et al., 2004;
Buckner et al., 2005;
Damoiseaux et al., 2011). Our most compelling imaging results demonstrate an
APOE genotype by gender interaction on posterior DMN connectivity. The precuneus/cuneus region of the posterior DMN showed a significant interaction, with the greatest reduction of functional connectivity in female
ε4 carriers (). Post-hoc testing was most notable for a 2000+ voxel cluster in the posterior cingulate/precuneus showing reduced connectivity in female
ε4 carriers compared to female
ε3 homozygotes (, ). The same comparison in males only showed reduced connectivity in
ε4 carriers in a small DMN cluster (, ). The small size and unusual location (not a core DMN region) of this cluster lead us to interpret this finding cautiously and strengthen our hypothesis that the
ε4 effect is mainly driven by female carriers. Comparing female and male
ε4 carriers revealed a decrease in female
ε4 carriers in three small but more strategically located DMN clusters (, ). In structural and functional connectivity analyses, the posterior cingulate/precuneus region is consistently found to be a core node in the DMN (
Hagmann et al., 2008;
Buckner et al., 2009). This region is structurally connected to the medial temporal lobes (
Greicius et al., 2009), the initial site of tau pathology in AD (
Braak and Braak, 1991). It shows reduced glucose metabolism early in AD and in asymptomatic
ε4 carriers (
Minoshima et al., 1995;
Reiman et al., 1996). Lastly, this region shows reduced connectivity in AD patients compared to controls (
Greicius et al., 2004) and in MCI patients compared to controls (
Sorg et al., 2007). Thus, the interaction of gender and
APOE status occurs in a core DMN node and in the node most tightly linked to AD.
In the anterior DMN we did not observe an
APOE genotype by gender interaction. However in the cluster highlighted to depict the directionality of the findings (), we saw additive effects of gender and
APOE genotype. This indicates that, although there is no
APOE genotype by gender interaction, the additive effects of decreased connectivity in
ε4 carriers and decreased connectivity in females, renders female
ε4 carriers most vulnerable to the observed
ε4 effect in this region. The observation of gender differences in resting state functional connectivity, including DMN regions, is consistent with many, but not all (
Weissman-Fogel et al., 2010), previous studies on this topic (
Liu et al., 2009;
Biswal et al., 2010;
Allen et al., 2011;
Filippi et al., 2012).
Our results may explain the prominent discrepancies in the four previous studies examining the effect of
APOE genotype on DMN connectivity in healthy older individuals (
Sheline et al., 2010;
Machulda et al., 2011;
Trachtenberg et al., 2011;
Westlye et al., 2011).
Sheline and colleagues (2010) found increases and decreases in DMN connectivity in
ε4 carriers,
Machulda and colleagues (2011) only found decreases,
Westlye and colleagues (2011) only found increases, and
Trachtenberg and colleagues (2011) found no differences in the DMN but reported differences in two hippocampal networks. The directionality of our findings is most compatible with
Machulda and colleagues (2011), who also showed decreased connectivity in
ε4 carriers. The discrepancy in the findings between our study and the prior four could be due to the different age ranges. The participants in our and Machulda and colleagues’ studies were older (mean age around 70 and 78, respectively) than those in the other three studies (mean ages around 61, 63, and 45). Perhaps more importantly, the ratio of males to females varied considerably across the previous studies. In the Sheline study there were 29 female and 9 male
ε4 carriers, and 43 female and 19 male
ε3 homozygotes; in the Machulda study gender was matched across
APOE genotype groups, with 21 females and 35 males in each group; in the Westlye study there were 20 female and 13 male
ε4 carriers, and 41 female and 21 male
ε3 homozygotes; and in the Trachtenberg study there were 17 female and 17 male
ε4 carriers and 10 female and 10 male
ε3 homozygotes. The discrepancy in findings across these previous studies might therefore be explained by an underlying and unexplored
APOE genotype by gender interaction.
We used the ADNI CSF dataset to obtain convergent evidence of an
APOE genotype by gender interaction in an independent cohort with an independent biomarker for AD. We found a main effect of
APOE on all three markers in the expected direction and an
APOE genotype by gender interaction in total tau levels, where female
ε4 carriers had significantly elevated levels compared to female
ε3 homozygotes while male
ε4 carriers and male
ε3 homozygotes had nearly identical levels. To our knowledge this is the first report of an
APOE genotype by gender interaction in a CSF biomarker of AD. Numerous studies have shown that AD and MCI patients have reduced CSF levels of Aß
1-42 and increased levels of p-tau and total tau (
Tarawneh and Holtzman, 2010). Shaw and colleagues have previously examined the ADNI healthy control dataset and noted an
APOE effect on Aß
1-42 levels (reduced in
ε4 carriers) and p-tau levels (increased in
ε4 carriers), but did not find a significant
APOE effect in total tau levels (
Shaw et al., 2009). Our analysis differs in that we excluded
ε2 carriers and examined an
APOE genotype by gender interaction. It is unclear why the
APOE genotype by gender interaction was detectable in total tau levels but not in p-tau or Aß
1-42 levels, though this might reflect the temporal progression of biomarkers in AD pathology. It is generally accepted that beta- amyloid pathology precedes tau pathology by many years (
Jack et al., 2010;
Jack et al., 2011). It is possible that p-tau changes precede total tau changes on the pathological progression to AD. This is consistent with the findings in Shaw et al., where healthy
ε4 carriers, collapsed across gender, differ from non
-ε4 carriers in Aß
1-42 levels and p-tau levels but not (yet) in total tau levels. In our analysis, female
ε4 carriers, presumably further along in their AD pathology, show changes in Aß
1-42 levels, p-tau levels, and total tau levels whereas male
ε4 carriers only manifest differences in the first two markers.
No differences or APOE genotype by gender interactions were observed for grey matter volume or memory performance. Changes in DMN functional connectivity and CSF tau protein levels seem to precede changes in brain structure and cognitive performance. This discrepancy suggests that resting-state functional connectivity and CSF protein analyses may therefore be more sensitive than cognitive testing or structural MRI measures as markers of preclinical AD.
Although we show that female
ε4 carriers have decreased DMN connectivity and increased CSF tau levels, we can only speculate as to the mechanism(s) behind this interaction. The most obvious possibility would be some interaction between
APOE status and sex hormone levels. Hundreds of studies in animals and humans have examined the effect of estrogen loss and replacement on cognition and dementia risk in older women (see (
Henderson, 2009) for a recent review). The negative outcome of the Women’s Health Initiative Memory Study, which showed an increased dementia risk in women on estrogen replacement therapy, has only added to the uncertainty regarding estrogen replacement (
Shumaker et al., 2004). Regarding our findings, it is notable that the few studies of estrogen and cognition that have stratified by
APOE status suggest that
APOE status may be critical in evaluating estrogen replacement (
Yaffe et al., 2000;
Kang and Grodstein, 2010).
We have demonstrated that gender influences the effect of APOE genotype on both DMN connectivity and CSF tau levels, and determined that the detrimental effect of the ε4 allele is most pronounced in females. Our results support previous work showing a higher prevalence of the ε4 allele among women with AD and, more critically, demonstrate that this interaction between APOE genotype and gender is detectable in the preclinical period. Future studies using biomarkers in the preclinical stages of disease should allow us to dissect the environmental, hormonal, and genetic factors that underlie this interaction which appears central to AD pathogenesis.